INTRODUCTION
Immunohistochemistry uses the specificity of antibodies to detect target molecules in tissues or cells, and it is a powerful technique in investigative toxicology (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) .
The enormous power and flexibility of the immunohistochemistry technique is reflected in Medline, which lists more than 70,000 articles with immunohistochemistry as a key word, all of which have been published in the last 10 yr. The targets are only limited by the availability of antisera. Currently, thousands of antisera are commercially available and more can be obtained privately.
In preclinical drug development, immunohistochemistry is commonly used to study constitutive protein expression (7, 8) , to identify a cell population based on protein expression (2, 4, 6, 10) , or to investigate in vitro or in vivo localization of protein drugs: for example, mononuclear infiltrates that are elicited by cytokine treatment by conventional staining but which can be classified according to protein expression by using antibodies directed against lymphocyte and macrophage cluster of differentiation (CD) markers (2, 4, 10) . In another example, constitutive endothelial-cell intercellular adhesion molecule (ICAM) or vascular cell adhesion molecule (VCAM) expression in a rat endotoxin model can help determine the mechanism of action in a preclinical drug candidate. The same antibodies can be useful in investigating druginduced vasculitis. The immunohistochemistry technique is also excellent to determine the efficacy of a drug, to highlight the toxic effects of a drug on target tissue, or as a diagnostic aid that can be used to classify tumors according to their protein expression. However, like any powerful technique, the immunohistochemistry technique needs to be properly managed in order to ensure that the results accurately reflect the desired end point.
SPECIFICITY OF REAGENTS
Lack of specificity of reagents is a problem that is more common than is generally recognized, and it can cause tremendous waste in terms of time and resources.
The immunohistochemical technique is limited by the physical limitations of the antibodies. Antibodies are proteins that recognize the shape of a small portion of a molecule called the epitope. The epitope is only about 4-6 amino acids long in the case of most protein targets. The presenting shape of the epitope is defined by the tertiary structure of the molecule, which may be dictated by other portions of the molecule or by adjacent molecules. The amino acids that make up a protein-epitope may not be contiguous and in some cases may span 2 molecules. Antibodies will typically cross-react with epitopes with a shape similar to that of the target epitope, even if the overall molecule is quite different. The specificity of an antibody is only as good as its selection or purification process.
Lack of specificity may be due to nonspecific stickiness of the antibody, but it is more commonly the result of cross-reactive binding of the antibody to a non-target tissue or molecule. Cross-reactivity of the antibodies with a non-target antigen is often the rule and not the exception. Monoclonal antibodies do not guarantee specificity. In a study in one biotechnology company in the 1980s, 13 of 14 monoclonal antibodies being developed as drugs cross-reacted with a non-target tissue. Two the cross-reactive antibodies were developed as anti-idiotype antibody reagents. While in a few cases the cross-reactivity was the result of target antigen expression on a non-target tissue, in many cases the antibodies cross-reacted with non-target molecules. This relative lack of specificity is also found in many commercially available antibodies unless great efforts have been taken to test the antibodies against a very broad range of other molecules. Because of the molecular complexity of tissue, there are few procedures that challenge the specificity of an antibody more than immunohistochemistry performed on tissue sections.
The best defense for controlling specificity is to never assume that a reagent is specific until it has been proven to be so. A literature search may identify references for the antibody as well as biochemical properties and tissue distribution of the antigen. Several methods can be used to confirm specificity. Correlation of the staining with the literature references for antigen distribution is a good start for assuring specificity. Comparing the binding of the test antibody with a second antibody known to bind to the same antigen but to a different epitope assures that the test antibody binds to the target molecule. Preblocking the primary antibody with the target antigen prior to incubation with tissue samples should block binding and should thereby confirm antibody binding to target antigen. In one example, an monoclonal IgM antibody (Mab) , which was in development as an anti-endotoxin drug, showed cross-reactivity with endothelial cells. Preblocking tissues with high concentrations of IgM did not affect Mab binding, suggesting that the binding was not due to nonspecific stickiness of the Mab or to Fc receptor binding. A second anti-endotoxin antibody did not bind to endothelium, indicating that binding was not due to endotoxin in the tissue. Finally, preblocking the Mab with its antigen (endotoxin) blocked tissue binding, thereby confirming that binding was occurring via the binding site. Other tests confirmed the Mab cross-reacted with tissue antigen unrelated to endotoxin. In addition to immunohistochemical procedures, antibody cross-reactivity can be screened by other immunological methods, including western blot analysis or enzyme-linked immunosorbent assay.
CONTROLLING STAINING FAILURES AND INTERASSAY VARIABILITY
Immunohistochemistry can be misleading if the staining study design is not carefully conceived and controlled. Because the method uses biological reagents, biological variability also must be managed. Careful selection of antibodies, appropriate staining controls, proper reagent storage, and meticulous records are the best defense against staining variability.
Improper reagent storage can be responsible for greater than 50% of immunohistochemistry failures, particularly in laboratories that store refrigerated reagents. As proteins, antibodies make a healthy meal for contaminating bacteria, yeasts, and fungi. Most antibodies sold as immunohistochemistry reagents have an agent added to prevent the growth of contaminants. A resistant organism commonly appears in most laboratories if immunohistochemistry is performed over a sufficiently long period of time. Two methods of managing contamination are (a) handling the reagents by using sterile techniques in a hood or (b) aliquoting and freezing them. Most antibody reagents can be stored frozen (despite the labeling), and they often give reproducible results long past the expiration date. A call to the manufacturer can generally identify which reagents can be stored frozen.
Detailed record keeping is a powerful tool for managing interexperimental variability, and implementation of detailed records frequently improves assay function. In one laboratory, greater than 30% of all staining studies failed, and the causes of the failures were unknown in nearly 100% of the cases. After implementing detailed records, the total number of failures dropped to less than 10%. Of those 10%, 92% of them contained a record of the error that caused the failure to occur, leaving only 8% of the causes of failure unknown. Part of the reason for the decline in staining failures was that keeping the detailed records made the users who were performing the staining more aware of the method details, such that mistakes were less likely to occur, and when errors did occur, they were more likely to be recognized. Ideally, all staining experiments are reviewed and a summary of the results is drafted even in staining experiments that contain a staining failure. Staining failure and artifacts tend to recur in the future, and detailed records of past experimental failures can be helpful years later when the problem occurs again but when no one remembers exactly what the problem was or how it was solved.
The main purposes of controls are to determine whether all parts of the staining assay are working and to shorten the time required to troubleshoot staining failures. If immunohistochemistry procedures worked all the time with perfect specificity, there would be no need for controls. But since they don't, the controls provide the best way to determine where improvements can be made and to assure that artifacts are not overinterpreted.
Antigen controls are tissues in which the antigen expression is known. A tissue that contains some structures that bear the antigen and other areas that do not bear the antigen makes an ideal antigen control tissue. Staining controls are designed to ensure that the antibodies and the detection system are working properly and to document any nonspecific cross-reactivity. Ideally, each reagent is controlled by a separate staining control.
Staining control can prevent misinterpretation and aid in the process of troubleshooting. Pretreatment of tissues with hydrogen peroxide neutralizes the peroxidase activity in red blood cells but it rarely completely inactivates the activity in the macrophages or eosinophils found in rat spleens. In studies that detect antigens present on relatively few splenic lymphocytes, this endogenous peroxidase activity could easily be misinterpreted as specific lymphocyte staining without a control in which only the detection agent diaminobenzidine (DAB) has been added to the tissue. Conversely, the lack of peroxidase activity in a spleen in the DAB control section may help uncover the error if the technician inadvertently forgot to add the hydrogen peroxide to the chromogen. In another example, a secondary antibody control that suddenly shows a high level of staining commonly indicates that the reagent has experienced microorganism contamination.
IN VITRO VERSUS IN VIVO LOCALIZATION
Immunohistochemistry is commonly used to determine where an antibody cross-reacts with tissue. It can also be invaluable for localizing antibodies in tissue following their injection into animals. In vitro localization rarely mimics the distribution of antibodies in vivo. For one reason, tissue preparation exposes antigen sites that are not accessible in vivo. For example, P-selection is found packaged in platelets and on the surface of activated endothelial cells and platelets. While in vivo, only the surface antigens are available, but the intracellular packaged P-selection is also available for in vitro staining.
In another example, an anti-human kidney antibody binds to all tissue structures in primate kidneys but binds particularly strongly to the interstitial collagen and tubule epithelium. While in vivo, the same antibody strongly localized in the glomerular basement membrane and, in fact, was originally created as an anti-glomerular basement membrane antibody. Minor binding to the tubular basement membrane also occurs in vivo, but cross-reactivity to other structures is absent. It is easy to understand the lack of binding to the intracellular sites, but lack of binding to the extracellular matrix is more difficult to explain. Logically, the extracellular antigens in the interstitium should be available for binding, but apparently they are not. On the other hand, in vitro antibody binding barely stains the glomerular basement membrane, but staining is very intense after in vivo exposure. The glomerulus has a tremendous capacity to filter relatively large volumes of plasma, which constantly exposes the basement membrane to fresh antibody until the sites are nearly saturated. The in vitro antibody staining correctly indicates the location of the antigens in tissue, but it does not predict which antigens will be accessible in vivo.
In vivo localization is optimally performed after the plasma levels of antibodies have decreased to very low levels. Unfortunately, some antibodies have half-lives that last from days to weeks, and it may not be practical to wait until the antibody is gone. Perfusion with saline prior to freezing or fixation can greatly reduce the background that is attributable to antibody in the plasma. If perfusion is not practical, soaking the tissues overnight before staining will help reduce some of the unbound antibody.
SUMMARY
Immunohistochemistry is a powerful technique used to localize specific molecules in tissues. Literally thousands of immunoreagents specific for an incredibly diverse number of molecules are commercially available, and some of these immunoreagents will detect minute quantities of target molecule in tissues. However, like any powerful technique, the staining study design must be carefully conceived and controlled to avoid misinterpretation.
